Randomized open-label trial of baclofen for relapse prevention in alcohol dependence

American Journal of Drug and Alcohol Abuse

Volumn 43, Issue 3, 2017, Pages 324-331

  Gupta, Manushree ^a,b   Verma, Pankaj ^b   Rastogi, Rajesh ^b   Arora, Sheetal ^b,c   Elwadhi, Deeksha ^a  

^a G B Pant Institute of Postgraduate Medical Education and Research   (India)

^b SAFDARJUNG HOSPITAL   (India)

^c ESIC MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

alcohol dependence; Baclofen; craving; GABA agonist; relapse prevention

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BACLOFEN; BENFOTIAMINE; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BENPHOTHIAMINE; THIAMINE;

ABSENCE OF SIDE EFFECTS; ADULT; ALCOHOL ABSTINENCE; ALCOHOLISM; ANXIETY ASSESSMENT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CRAVING; DRINKING; FEMALE; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DRINKING SCALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; TREATMENT DURATION; UNIFIED HUNTINGTON DISEASE RATING SCALE; ANALOGS AND DERIVATIVES; ANXIETY; COMPARATIVE STUDY; DRINKING BEHAVIOR; DRUG EFFECTS; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; PREVENTION AND CONTROL; PROCEDURES; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL DRINKING; ALCOHOLISM; ANXIETY; BACLOFEN; CRAVING; GABA-B RECEPTOR AGONISTS; HUMANS; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; SECONDARY PREVENTION; THIAMINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84994091885     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990.2016.1240797     Document Type: Article

References (31)

1. Edwards G, Gross MM., Alcohol dependence:provisional description of a clinical syndrome. Br Med J 1976;1:1058–1061.
2. WHO Global status report on alcohol and health 2014. Available at:http://www.who.int/substance_abuse/publications/global_alcohol_report/msb_gsr_2014_2.pdf?ua=1 [last accessed 21 July 2016]
3. Rehm J., The risks associated with alcohol use and alcoholism. Alcohol Res Health 2011;34:135–143.
4. UNODC. National Survey on Extent, Pattern and Trends of Drug Abuse in India. New Delhi, 2004. Available from:http://www.unodc.org/pdf/india/presentations/india_national_survey_2004.pdf [last accessed 20 July 2016]
5. Miller WR, Hester RK., Inpatient alcoholism treatment:who benefits? Am Psychol 1986;41:794–805.
6. Krishnan-Sarin S, O’Malley S, Krystal JH., Treatment implications:using neuroscience to guide the development of new pharmacotherapies for alcoholism. Alcohol Res Health 2008;31:400–407.
7. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism:a Veterans Administration cooperative study. JAMA1986;256:1449–1455.
8. Bouza C, Angeles M, Muñoz A, Amate JM., Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence:a systematic review. Addiction 2004;99:811–828.
9. Mann K, Lehert P, Morgan MY., The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals:results of a meta-analysis. Alcohol Clin Exp Res 2004;28:51–63.
10. Addolorato G, Abenavoli L, Leggio L, et al. How many cravings? Pharmacological aspects of craving treatment in alcohol addiction:a review. Neuropsychobiology 2005;51:59–61.
11. Colombo G, Addolorato G, Agabio R, et al. Role of GABA (B) receptor in alcohol dependence:reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotox Res 2004;6:403–414.
12. Baclofen:Drug information. In:UpToDate.DS, Basow, ed. UpToDate Waltham, MA, 2010.
13. Addolorato G, Caputo F, Capristo et al. Baclofen efficacy in reducing alcohol craving and intake:a preliminary double-blind randomised controlled study. Alcohol 2002;37:504–508.
14. Flannery BA, Garbutt JC, Cody MW, et al. Baclofen for alcohol dependence:a preliminary open-label study. Alcohol Clin Exp Res 2004;28:1517–1523.
15. Garbutt JC, Kampov-Polevoy AB, Gallop R, et al. Efficacy and safety of baclofen for alcohol dependence:a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010;34:1849–1857.
16. World Health Organization. International statistical classification of diseases and related health problems, 10th Revision (ICD-10). Geneva:WHO, 1992.
17. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.):the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin Psychiatry 1998;59(suppl 20):22–33.
18. Anton RF, Moak DH, Latham PK., The obsessive compulsive drinking scale:a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry1996;53:225–231.
19. Hamilton M., The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–55.
20. Hamilton M., A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.AddoloratoG, Leggio L, Ferrulli A et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent participants with liver cirrhosis:randomised, double-blind controlled study. Lancet 2007;370:1915–1922.
21. Cutler RB, Fishbain DA., Are alcoholism treatments effective? The Project MATCH data. BMC Public Health 2005;5:75.
22. Drake RG, Davis LL, Cates ME, et al. Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother 2003;37:1177–1181.
23. Manteghi AA, Hebrani P, Mortezania M, et al. Baclofen add-on to citalopram in treatment of posttraumatic stress disorder. J Clin Psychopharmacol 2014;34:240–243.
24. WR, Miller,Sanchez, VC., Motivating young adults for treatment and lifestyle change. In:Howard, G, ed. Issues in alcohol use and misuse by young adults. Notre Dame, IN:University of Notre Dame Press; 1993
25. Schulz KF, Altman DG, D., Moher CONSORT 2010 statement:updated guidelines for reporting parallel group randomised trials. J Pharma Pharmacoth 2010;1:100–107.
26. Driessen M, Meier S, Hill A, et al. The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol 2001;36:249–255.
27. Agabio R, Colombo G., GABAB receptor ligands for the treatment of alcohol use disorder:preclinical and clinical evidence. Front Neurosci 2014;8:140.
28. Anton RF, O’Malley SS, Ciraulo DA, et al. COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence:the COMBINE study:a randomized controlled trial. JAMA 2006;295:2003–2017.
29. Krystal JH, Cramer JA, Krol WF, et al. Veterans Affairs Naltrexone Cooperative Study 425 Group. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001;345:1734–1739.
30. Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome:a comparative study vs diazepam. Am J Med 2006;119:276.e13–e18.
31. Ponizovsky AM, Rosca P, Aronovich E, et al. Baclofen as add-on to standard psychosocial treatment for alcohol dependence:a randomized, double-blind, placebo-controlled trial with 1 year follow-up. J Subst Abuse Treat 2015;52:24–30.